| Year |
Citation |
Score |
| 2024 |
Simoni-Nieves A, Lindzen M, Giri S, Gupta N, Chatterjee R, Selvadurai BR, Van Daele M, Love D, Haga Y, Romaniello D, Salame TM, Zerbib M, Oren R, Tsutsumi Y, Lauriola M, ... ... Yarden Y, et al. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib. Cell Reports. Medicine. 101703. PMID 39216477 DOI: 10.1016/j.xcrm.2024.101703 |
0.346 |
|
| 2023 |
Marrocco I, Yarden Y. Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators. Cancers. 15. PMID 37894376 DOI: 10.3390/cancers15205009 |
0.352 |
|
| 2023 |
Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, ... Yarden Y, et al. L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell Reports. Medicine. 101142. PMID 37557179 DOI: 10.1016/j.xcrm.2023.101142 |
0.314 |
|
| 2023 |
Hedegger K, Blutke A, Hommel T, Auer KE, Nataraj NB, Lindzen M, Yarden Y, Dahlhoff M. Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma. Molecular Oncology. PMID 37341059 DOI: 10.1002/1878-0261.13473 |
0.375 |
|
| 2022 |
Nataraj NB, Noronha A, Lee JS, Ghosh S, Mohan Raju HR, Sekar A, Zuckerman B, Lindzen M, Tarcitano E, Srivastava S, Selitrennik M, Livneh I, Drago-Garcia D, Rueda O, Caldas C, ... ... Yarden Y, et al. Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. Cell Reports. 38: 110418. PMID 35196484 DOI: 10.1016/j.celrep.2022.110418 |
0.782 |
|
| 2021 |
Gaviraghi M, Rabellino A, Andolfo A, Brand M, Brombin C, Bagnato P, De Feudis G, Raimondi A, Locatelli A, Tosoni D, Mazza D, Gianni L, Tonon G, Yarden Y, Tacchetti C, et al. Author Correction: Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr phosphorylation. Scientific Reports. 11: 18202. PMID 34497338 DOI: 10.1038/s41598-021-97699-1 |
0.384 |
|
| 2021 |
Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers. 13. PMID 34206026 DOI: 10.3390/cancers13112748 |
0.412 |
|
| 2021 |
Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers. 13. PMID 34206026 DOI: 10.3390/cancers13112748 |
0.412 |
|
| 2021 |
Uribe ML, Dahlhoff M, Batra RN, Nataraj NB, Haga Y, Drago-Garcia D, Marrocco I, Sekar A, Ghosh S, Vaknin I, Lebon S, Kramarski L, Tsutsumi Y, Choi I, Rueda OM, ... ... Yarden Y, et al. TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis. Science Signaling. 14. PMID 34158398 DOI: 10.1126/scisignal.abe6156 |
0.316 |
|
| 2020 |
Gaviraghi M, Rabellino A, Andolfo A, Brand M, Brombin C, Bagnato P, De Feudis G, Raimondi A, Locatelli A, Tosoni D, Mazza D, Gianni L, Tonon G, Yarden Y, Tacchetti C, et al. Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr phosphorylation. Scientific Reports. 10: 16906. PMID 33037285 DOI: 10.1038/s41598-020-73835-1 |
0.5 |
|
| 2020 |
Shenoy A, Belugali Nataraj N, Perry G, Loayza Puch F, Nagel R, Marin I, Balint N, Bossel N, Pavlovsky A, Barshack I, Kaufman B, Agami R, Yarden Y, Dadiani M, Geiger T. Proteomic patterns associated with response to breast cancer neoadjuvant treatment. Molecular Systems Biology. 16: e9443. PMID 32960509 DOI: 10.15252/Msb.20209443 |
0.305 |
|
| 2020 |
Romaniello D, Marrocco I, Belugali Nataraj N, Ferrer I, Drago-Garcia D, Vaknin I, Oren R, Lindzen M, Ghosh S, Kreitman M, Kittel JC, Gaborit N, Bergado Baez G, Sanchez B, Eilam R, ... ... Yarden Y, et al. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers. 12. PMID 32847130 DOI: 10.3390/Cancers12092394 |
0.486 |
|
| 2020 |
Ghosh S, Marrocco I, Yarden Y. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research. 147: 1-57. PMID 32593398 DOI: 10.1016/Bs.Acr.2020.04.002 |
0.514 |
|
| 2019 |
Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, ... ... Yarden Y, et al. Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. The Journal of Clinical Investigation. PMID 31671073 DOI: 10.1172/Jci126896 |
0.397 |
|
| 2019 |
Srivastava S, Nataraj NB, Sekar A, Ghosh S, Bornstein C, Drago-Garcia D, Roth L, Romaniello D, Marrocco I, David E, Gilad Y, Lauriola M, Rotkopf R, Kimchi A, Haga Y, ... ... Yarden Y, et al. ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. Cell Reports. 29: 104-117.e4. PMID 31577941 DOI: 10.1016/J.Celrep.2019.08.088 |
0.464 |
|
| 2019 |
Maron R, Schechter B, Nataraj NB, Ghosh S, Romaniello D, Marrocco I, Noronha A, Carvalho S, Yarden Y, Sela M. Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies. Biochemical and Biophysical Research Communications. PMID 30952434 DOI: 10.1016/J.Bbrc.2019.03.204 |
0.458 |
|
| 2019 |
Kubli SP, Bassi C, Roux C, Wakeham A, Göbl C, Zhou W, Jafari SM, Snow B, Jones L, Palomero L, Thu KL, Cassetta L, Soong D, Berger T, Ramachandran P, ... ... Yarden Y, et al. AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30733286 DOI: 10.1073/Pnas.1815126116 |
0.475 |
|
| 2019 |
Marrocco I, Romaniello D, Yarden Y. Cancer Immunotherapy: The Dawn of Antibody Cocktails. Methods in Molecular Biology (Clifton, N.J.). 1904: 11-51. PMID 30539465 DOI: 10.1007/978-1-4939-8958-4_2 |
0.338 |
|
| 2018 |
Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman MS, Srivastava S, Ghosh S, Lindzen M, Salame TM, Onn A, Bar J, Yarden Y. A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29967248 DOI: 10.1158/1078-0432.Ccr-18-0450 |
0.36 |
|
| 2018 |
Arandkar S, Furth N, Elisha Y, Nataraj NB, van der Kuip H, Yarden Y, Aulitzky W, Ulitsky I, Geiger B, Oren M. Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proceedings of the National Academy of Sciences of the United States of America. PMID 29866855 DOI: 10.1073/Pnas.1719076115 |
0.314 |
|
| 2018 |
Kreitman M, Noronha A, Yarden Y. Irreversible Modifications of Receptor Tyrosine Kinases. Febs Letters. PMID 29790151 DOI: 10.1002/1873-3468.13095 |
0.586 |
|
| 2018 |
Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN, Roberts S, Zanetti-Domingues LC, Hirsch M, Collu F, George R, Ortiz-Zapater E, Barber PR, Vojnovic B, Yarden Y, et al. Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface. Elife. 7. PMID 29712619 DOI: 10.7554/Elife.32271 |
0.449 |
|
| 2018 |
Roth L, Srivastava S, Lindzen M, Sas-Chen A, Sheffer M, Lauriola M, Enuka Y, Noronha A, Mancini M, Lavi S, Tarcic G, Pines G, Nevo N, Heyman O, Ziv T, ... ... Yarden Y, et al. SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors. Science Signaling. 11. PMID 29382783 DOI: 10.1126/Scisignal.Aan0949 |
0.463 |
|
| 2018 |
Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN, Roberts S, Zanetti-Domingues LC, Hirsch M, Collu F, George R, Ortiz-Zapater E, Barber PR, Vojnovic B, Yarden Y, et al. Author response: Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface Elife. DOI: 10.7554/Elife.32271.037 |
0.337 |
|
| 2017 |
Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, ... ... Yarden Y, et al. An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors. Embo Molecular Medicine. PMID 29212784 DOI: 10.15252/Emmm.201708076 |
0.622 |
|
| 2017 |
Enuka Y, Feldman ME, Chowdhury A, Srivastava S, Lindzen M, Sas-Chen A, Massart R, Cheishvili D, Suderman MJ, Zaltsman Y, Mazza CA, Shukla K, Körner C, Furth N, Lauriola M, ... ... Yarden Y, et al. Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone. Nucleic Acids Research. PMID 29036586 DOI: 10.1093/Nar/Gkx865 |
0.377 |
|
| 2017 |
Dahlhoff M, Gaborit N, Bultmann S, Leonhardt H, Yarden Y, Schneider MR. CRISPR-assisted receptor deletion reveals distinct roles for ERBB2 and ERBB3 in skin keratinocytes. The Febs Journal. PMID 28805349 DOI: 10.1111/Febs.14196 |
0.486 |
|
| 2017 |
Golan-Lavi R, Giacomelli C, Fuks G, Zeisel A, Sonntag J, Sinha S, Köstler W, Wiemann S, Korf U, Yarden Y, Domany E. Coordinated Pulses of mRNA and of Protein Translation or Degradation Produce EGF-Induced Protein Bursts. Cell Reports. 18: 3129-3142. PMID 28355565 DOI: 10.1016/J.Celrep.2017.03.014 |
0.313 |
|
| 2017 |
Sas-Chen A, Srivastava S, Yarden Y. The short and the long: non-coding RNAs and growth factors in cancer progression. Biochemical Society Transactions. 45: 51-64. PMID 28202659 DOI: 10.1042/Bst20160131 |
0.302 |
|
| 2017 |
Tarcic O, Granit RZ, Pateras IS, Masury H, Maly B, Zwang Y, Yarden Y, Gorgoulis VG, Pikarsky E, Ben-Porath I, Oren M. RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer. Cell Death and Differentiation. PMID 28157208 DOI: 10.1038/Cdd.2016.126 |
0.739 |
|
| 2016 |
Gelfo V, Rodia MT, Pucci M, Dall'Ora M, Santi S, Solmi R, Roth L, Lindzen M, Bonafè M, Bertotti A, Caramelli E, Lollini PL, Trusolino L, Yarden Y, D'Uva G, et al. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. Oncotarget. PMID 27708224 DOI: 10.18632/Oncotarget.12354 |
0.406 |
|
| 2016 |
Bublil EM, Cohen T, Arnusch CJ, Peleg A, Pines G, Lavi S, Yarden Y, Shai Y. Interfering with the Dimerization of the ErbB Receptors by Transmembrane Domain Derived Peptides Inhibits Tumorigenic Growth in Vitro and In Vivo. Biochemistry. PMID 27575020 DOI: 10.1021/Acs.Biochem.6B00450 |
0.512 |
|
| 2016 |
Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F, Ulitsky I, Diederichs S, ... ... Yarden Y, et al. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. Embo Molecular Medicine. PMID 27485121 DOI: 10.15252/Emmm.201606198 |
0.42 |
|
| 2016 |
Tóth G, Szöőr Á, Simon L, Yarden Y, Szöllősi J, Vereb G. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. Mabs. 0. PMID 27380003 DOI: 10.1080/19420862.2016.1204503 |
0.321 |
|
| 2016 |
Grossman M, Ben-Chetrit N, Zhuravlev A, Afik R, Bassat E, Solomonov I, Yarden Y, Sagi I. Tumor cell invasion can be blocked by modulators of collagen fibril alignment that control assembly of the extracellular matrix. Cancer Research. PMID 27221706 DOI: 10.1158/0008-5472.Can-15-2813 |
0.315 |
|
| 2016 |
Carvalho S, Levi-Schaffer F, Sela M, Yarden Y. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review X. British Journal of Pharmacology. PMID 26833433 DOI: 10.1111/Bph.13450 |
0.351 |
|
| 2016 |
Donzelli S, Cioce M, Muti P, Strano S, Yarden Y, Blandino G. MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. Seminars in Cell & Developmental Biology. PMID 26773212 DOI: 10.1016/J.Semcdb.2015.12.020 |
0.463 |
|
| 2016 |
Zhu G, Saboor-Yaraghi A, Yarden Y, Santos J, JC N. Downregulating oncogenic receptor: From bench to clinic Hematology & Medical Oncology. 1. DOI: 10.15761/HMO.1000106 |
0.319 |
|
| 2016 |
Tóth G, Szöőr Á, Simon L, Yarden Y, Szöllősi J, Vereb G. Abstract B069: The best is not enough—when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B069 |
0.317 |
|
| 2015 |
Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Research. PMID 26657629 DOI: 10.1093/Nar/Gkv1367 |
0.323 |
|
| 2015 |
Gaborit N, Lindzen M, Yarden Y. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Human Vaccines & Immunotherapeutics. 1-17. PMID 26529100 DOI: 10.1080/21645515.2015.1102809 |
0.453 |
|
| 2015 |
Schneider MR, Yarden Y. The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors. Oncogene. PMID 26434585 DOI: 10.1038/Onc.2015.372 |
0.467 |
|
| 2015 |
Mancini M, Yarden Y. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Seminars in Cell & Developmental Biology. PMID 26428295 DOI: 10.1016/J.Semcdb.2015.09.018 |
0.416 |
|
| 2015 |
Kedmi M, Sas-Chen A, Yarden Y. MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression. Journal of Clinical Medicine. 4: 1578-99. PMID 26287249 DOI: 10.3390/Jcm4081578 |
0.438 |
|
| 2015 |
Mahlknecht G, Maron R, Schechter B, Yarden Y, Sela M. Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor binding. Biochemical and Biophysical Research Communications. 465: 218-24. PMID 26248137 DOI: 10.1016/J.Bbrc.2015.07.157 |
0.395 |
|
| 2015 |
Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Research. 75: 3554-67. PMID 26206558 DOI: 10.1158/0008-5472.Can-14-2959 |
0.458 |
|
| 2015 |
Mahlknecht G, Sela M, Yarden Y. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy. Methods in Molecular Biology (Clifton, N.J.). 1317: 3-15. PMID 26072398 DOI: 10.1007/978-1-4939-2727-2_1 |
0.437 |
|
| 2015 |
Mancini M, Gaborit N, Lindzen M, Salame TM, Dall'Ora M, Sevilla-Sharon M, Abdul-Hai A, Downward J, Yarden Y. Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. Science Signaling. 8: ra53. PMID 26038598 DOI: 10.1126/Scisignal.Aaa0725 |
0.686 |
|
| 2015 |
Yarden Y, Sela M. Cancer Immunotherapy: More Is (Much) Better. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4030-2. PMID 26019173 DOI: 10.1158/1078-0432.Ccr-15-0996 |
0.34 |
|
| 2015 |
Carvalho S, Lindzen M, Lauriola M, Shirazi N, Sinha S, Abdul-Hai A, Levanon K, Korach J, Barshack I, Cohen Y, Onn A, Mills G, Yarden Y. An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors. Oncogene. PMID 25915843 DOI: 10.1038/Onc.2015.93 |
0.48 |
|
| 2015 |
D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, Weisinger K, Bassat E, Rajchman D, Yifa O, Lysenko M, Konfino T, Hegesh J, Brenner O, Neeman M, ... Yarden Y, et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nature Cell Biology. 17: 627-38. PMID 25848746 DOI: 10.1038/Ncb3149 |
0.325 |
|
| 2015 |
Kedmi M, Ben-Chetrit N, Körner C, Mancini M, Ben-Moshe NB, Lauriola M, Lavi S, Biagioni F, Carvalho S, Cohen-Dvashi H, Schmitt F, Wiemann S, Blandino G, Yarden Y. EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Science Signaling. 8: ra29. PMID 25783158 DOI: 10.1126/Scisignal.2005866 |
0.745 |
|
| 2015 |
Cohen-Dvashi H, Ben-Chetrit N, Russell R, Carvalho S, Lauriola M, Nisani S, Mancini M, Nataraj N, Kedmi M, Roth L, Köstler W, Zeisel A, Yitzhaky A, Zylberg J, Tarcic G, ... ... Yarden Y, et al. Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. Embo Molecular Medicine. 7: 299-314. PMID 25678558 DOI: 10.15252/Emmm.201404134 |
0.769 |
|
| 2015 |
Ben-Chetrit N, Chetrit D, Russell R, Körner C, Mancini M, Abdul-Hai A, Itkin T, Carvalho S, Cohen-Dvashi H, Koestler WJ, Shukla K, Lindzen M, Kedmi M, Lauriola M, Shulman Z, ... ... Yarden Y, et al. Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Science Signaling. 8: ra7. PMID 25605973 DOI: 10.1126/Scisignal.2005537 |
0.774 |
|
| 2015 |
Gaborit N, Abdul-Hai A, Mancini M, Lindzen M, Lavi S, Leitner O, Mounier L, Chentouf M, Dunoyer S, Ghosh M, Larbouret C, Chardès T, Bazin H, Pèlegrin A, Sela M, ... Yarden Y, et al. Examination of HER3 targeting in cancer using monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America. 112: 839-44. PMID 25564668 DOI: 10.1073/Pnas.1423645112 |
0.483 |
|
| 2015 |
Rosenbaum S, Capparelli C, Berman-Booty LD, Gaborit N, Zhan T, Davies MA, Setiady YY, Yarden Y, Aplin AE. Abstract A52: Extracellular matrix regulation of ErbB3 in a subset of wild-type BRAF/NRAS melanoma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-A52 |
0.512 |
|
| 2015 |
Capparelli C, Rosenbaum S, Berman-Booty LD, Gaborit N, Zhan T, Davies MA, Setiady YY, Yarden Y, Aplin AE. Abstract A09: ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A09 |
0.459 |
|
| 2015 |
Lauriola M, Enuka Y, Zeisel A, D'Uva G, Roth L, Carvalho S, Solmi R, Domany E, Yarden Y. Abstract 3475: Diurnal suppression of EGFR signaling by glucocorticoids: implications for tumor progression and treatment Cancer Research. 75: 3475-3475. DOI: 10.1158/1538-7445.Am2015-3475 |
0.543 |
|
| 2015 |
Lindzen M, Carvalho S, Yarden Y. Abstract A58: Antibodies to amphiregulin, an abundant growth factor in patients' fluids, inhibits tumor growth Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A58 |
0.437 |
|
| 2015 |
Köstler WJ, Yarden Y. HER Molecular Oncology: Causes of Cancer and Targets For Treatment. 85-109. DOI: 10.1017/CBO9781139046947.011 |
0.515 |
|
| 2015 |
Pareja F, Pines G, Yarden Y. The EGFR/ERBB receptor family Receptor Tyrosine Kinases: Family and Subfamilies. 107-164. DOI: 10.1007/978-3-319-11888-8_4 |
0.508 |
|
| 2015 |
Mahlknecht G, Sela M, Yarden Y. Aptamer targeting the ERBB2 receptor tyrosine kinase for applications in tumor therapy Methods in Molecular Biology. 1317: 3-15. DOI: 10.1007/978-1-4939-2727-2_1 |
0.355 |
|
| 2015 |
Wheeler DL, Yarden Y. Receptor tyrosine kinases: Structure, functions and role in human disease Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. 1-440. DOI: 10.1007/978-1-4939-2053-2 |
0.355 |
|
| 2014 |
Lauriola M, Enuka Y, Zeisel A, D'Uva G, Roth L, Sharon-Sevilla M, Lindzen M, Sharma K, Nevo N, Feldman M, Carvalho S, Cohen-Dvashi H, Kedmi M, Ben-Chetrit N, Chen A, ... ... Yarden Y, et al. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nature Communications. 5: 5073. PMID 25278152 DOI: 10.1038/Ncomms6073 |
0.809 |
|
| 2014 |
Kiuchi T, Ortiz-Zapater E, Monypenny J, Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B, Rolfe DJ, de Rinaldis E, Dafou D, Simpson MA, Woodman N, Pinder S, ... ... Yarden Y, et al. The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. Science Signaling. 7: ra78. PMID 25140053 DOI: 10.1126/Scisignal.2005157 |
0.462 |
|
| 2014 |
Feldman ME, Yarden Y. Steering tumor progression through the transcriptional response to growth factors and stroma. Febs Letters. 588: 2407-14. PMID 24873881 DOI: 10.1016/J.Febslet.2014.05.036 |
0.378 |
|
| 2014 |
Burgess AW, Henis YI, Hynes NE, Jovin T, Levitzki A, Pinkas-Kramarski R, Yarden Y. EGF receptor family: twisting targets for improved cancer therapies. Growth Factors (Chur, Switzerland). 32: 74-81. PMID 24641597 DOI: 10.3109/08977194.2014.896355 |
0.543 |
|
| 2014 |
Schneider MR, Yarden Y. Structure and function of epigen, the last EGFR ligand. Seminars in Cell & Developmental Biology. 28: 57-61. PMID 24374012 DOI: 10.1016/J.Semcdb.2013.12.011 |
0.501 |
|
| 2013 |
Köstler WJ, Zeisel A, Körner C, Tsai JM, Jacob-Hirsch J, Ben-Chetrit N, Sharma K, Cohen-Dvashi H, Yitzhaky A, Lader E, Tschulena U, Rechavi G, Domany E, Wiemann S, Yarden Y. Epidermal growth-factor-induced transcript isoform variation drives mammary cell migration. Plos One. 8: e80566. PMID 24324612 DOI: 10.1371/Journal.Pone.0080566 |
0.782 |
|
| 2013 |
Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harbor Perspectives in Biology. 5: a016949. PMID 24296170 DOI: 10.1101/Cshperspect.A016949 |
0.451 |
|
| 2013 |
D'Uva G, Bertoni S, Lauriola M, De Carolis S, Pacilli A, D'Anello L, Santini D, Taffurelli M, Ceccarelli C, Yarden Y, Montanaro L, Bonafé M, Storci G. Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. Plos One. 8: e80742. PMID 24260469 DOI: 10.1371/Journal.Pone.0080742 |
0.309 |
|
| 2013 |
Maron R, Schechter B, Mancini M, Mahlknecht G, Yarden Y, Sela M. Inhibition of pancreatic carcinoma by homo-and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 Proceedings of the National Academy of Sciences of the United States of America. 110: 15389-15394. PMID 24003140 DOI: 10.1073/Pnas.1313857110 |
0.517 |
|
| 2013 |
Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth Proceedings of the National Academy of Sciences of the United States of America. 110: 8170-8175. PMID 23630281 DOI: 10.1073/Pnas.1302594110 |
0.469 |
|
| 2013 |
Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit N, Sela M, Yarden Y. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR Proceedings of the National Academy of Sciences of the United States of America. 110: 1815-1820. PMID 23319610 DOI: 10.1073/Pnas.1220763110 |
0.806 |
|
| 2013 |
Ben-Chetrit N, Tarcic G, Yarden Y. ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype. Cell Adhesion & Migration. 7: 33-7. PMID 23076209 DOI: 10.4161/Cam.22263 |
0.448 |
|
| 2013 |
Zeisel A, Yitzhaky A, Koerner C, Lauriola M, Cohen-Dvashi H, Köstler WJ, Yarden Y, Wiemann S, Domany E. qCMA: a desktop application for quantitative collective cell migration analysis. Journal of Biomolecular Screening. 18: 356-60. PMID 23042078 DOI: 10.1177/1087057112461940 |
0.702 |
|
| 2013 |
Barnea I, Haif S, Keshet R, Karaush V, Lev-Ari S, Khafif A, Shtabsky A, Yarden Y, Vexler A, Ben Yosef R. Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies. Head & Neck. 35: 399-407. PMID 22367849 DOI: 10.1002/Hed.22967 |
0.371 |
|
| 2013 |
Ben-Chetrit N, Chetrit D, Koerner C, Carvalho S, Symons M, Schmitt F, Wiemann S, Ehrlich M, Yarden Y. Abstract A84: Synaptojanin-2 and microRNA-31 control invadopodia and metastasis by regulating vesicular trafficking Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-A84 |
0.388 |
|
| 2013 |
Capparelli C, Gaborit N, Yarden Y, Aplin A. Abstract C44: Targeting neuregulin1-ErbB3 signaling in wild-type BRAF/NRAS melanoma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C44 |
0.475 |
|
| 2012 |
Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, ... ... Yarden Y, et al. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. Embo Molecular Medicine. 4: 1214-29. PMID 23125021 DOI: 10.1002/Emmm.201201483 |
0.32 |
|
| 2012 |
Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews. Cancer. 12: 553-63. PMID 22785351 DOI: 10.1038/Nrc3309 |
0.354 |
|
| 2012 |
Zwang Y, Oren M, Yarden Y. Consistency test of the cell cycle: roles for p53 and EGR1. Cancer Research. 72: 1051-4. PMID 22315347 DOI: 10.1158/0008-5472.Can-11-3382 |
0.736 |
|
| 2012 |
Avraham R, Yarden Y. Regulation of signalling by microRNAs. Biochemical Society Transactions. 40: 26-30. PMID 22260661 DOI: 10.1042/Bst20110623 |
0.328 |
|
| 2012 |
Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, Zwang Y, Katz M, Ben-Chetrit N, Jacob-Hirsch J, Virgilio L, Rechavi G, Mavrothalassitis G, Mills GB, Domany E, ... Yarden Y, et al. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 1582-92. PMID 22198386 DOI: 10.1096/Fj.11-194654 |
0.784 |
|
| 2012 |
Pareja F, Ferraro DA, Rubin C, Cohen-Dvashi H, Zhang F, Aulmann S, Ben-Chetrit N, Pines G, Navon R, Crosetto N, Köstler W, Carvalho S, Lavi S, Schmitt F, Dikic I, ... ... Yarden Y, et al. Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. Oncogene. 31: 4599-608. PMID 22179831 DOI: 10.1038/Onc.2011.587 |
0.85 |
|
| 2012 |
Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, ... ... Yarden Y, et al. Modeling invasive breast cancer: Growth factors propel progression of HER2-positive premalignant lesions Oncogene. 31: 3569-3583. PMID 22139081 DOI: 10.1038/Onc.2011.547 |
0.508 |
|
| 2012 |
Lindzen M, Carvalho S, Starr A, Ben-Chetrit N, Pradeep CR, Köstler WJ, Rabinkov A, Lavi S, Bacus SS, Yarden Y. A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene. 31: 3505-15. PMID 22105361 DOI: 10.1038/Onc.2011.518 |
0.514 |
|
| 2012 |
Pradeep CR, Köstler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J, Rechavi G, Nair HB, Hennessy BT, Gonzalez-Angulo AM, Tekmal RR, Ben-Porath I, Mills GB, Domany E, Yarden Y. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene. 31: 907-17. PMID 21743488 DOI: 10.1038/Onc.2011.279 |
0.413 |
|
| 2012 |
Emde A, Köstler WJ, Yarden Y. Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Critical Reviews in Oncology/Hematology. 84: e49-57. PMID 20951604 DOI: 10.1016/J.Critrevonc.2010.09.002 |
0.488 |
|
| 2012 |
Yarden Y. Abstract BL-1: Brinker Award Lecture: How Does HER2 Contribute to Breast Cancer Progression? Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Bl-1 |
0.605 |
|
| 2011 |
Emde A, Mahlknecht G, Maslak K, Ribba B, Sela M, Possinger K, Yarden Y. Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance. Translational Oncology. 4: 293-300. PMID 21966546 DOI: 10.1593/Tlo.11127 |
0.489 |
|
| 2011 |
Witsch EJ, Mahlknecht G, Wakim J, Sertchook R, Bublil E, Yarden Y, Sela M. Generation and characterization of peptide mimotopes specific for anti erbb-2 monoclonal antibodies International Immunology. 23: 391-403. PMID 21602175 DOI: 10.1093/Intimm/Dxr028 |
0.309 |
|
| 2011 |
Zwang Y, Sas-Chen A, Drier Y, Shay T, Avraham R, Lauriola M, Shema E, Lidor-Nili E, Jacob-Hirsch J, Amariglio N, Lu Y, Mills GB, Rechavi G, Oren M, Domany E, ... Yarden Y, et al. Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Molecular Cell. 42: 524-35. PMID 21596316 DOI: 10.1016/J.Molcel.2011.04.017 |
0.741 |
|
| 2011 |
Yarden Y. The biological framework: translational research from bench to clinic. The Oncologist. 16: 23-9. PMID 21278438 DOI: 10.1634/Theoncologist.2011-S1-23 |
0.413 |
|
| 2011 |
Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nature Reviews. Molecular Cell Biology. 12: 104-17. PMID 21252999 DOI: 10.1038/Nrm3048 |
0.515 |
|
| 2011 |
Emde A, Pradeep CR, Ferraro DA, Ben-Chetrit N, Sela M, Ribba B, Kam Z, Yarden Y. Combining epitope-distinct antibodies to HER2: Cooperative inhibitory effects on invasive growth Oncogene. 30: 1631-1642. PMID 21132012 DOI: 10.1038/Onc.2010.547 |
0.404 |
|
| 2011 |
Yarden Y, Pareja F. Abstract SY23-02: RTK endocytosis and other feedback mechanisms in cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Sy23-02 |
0.547 |
|
| 2011 |
Pradeep C, Koestler W, Lauriola M, Nair H, Rao R, Mills G, Yarden Y. P2-03-04: Novel Pathways Underlying the Initiation and Transition of DCIS to IDC of HER2−Overexpressing Breast Cancer Model. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-03-04 |
0.417 |
|
| 2011 |
Köstler WJ, Yarden Y. The EGFR/ErbB family in breast cancer: From signalling to therapy Milestones in Drug Therapy. 38: 1-32. DOI: 10.1007/978-3-0346-0094-1_1 |
0.369 |
|
| 2010 |
Tarcic G, Yarden Y. MAP Kinase activation by receptor tyrosine kinases: in control of cell migration. Methods in Molecular Biology (Clifton, N.J.). 661: 125-35. PMID 20811980 DOI: 10.1007/978-1-60761-795-2_7 |
0.56 |
|
| 2010 |
Bublil EM, Pines G, Patel G, Fruhwirth G, Ng T, Yarden Y. Kinase-mediated quasi-dimers of EGFR. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 4744-55. PMID 20682838 DOI: 10.1096/Fj.10-166199 |
0.539 |
|
| 2010 |
Pines G, Huang PH, Zwang Y, White FM, Yarden Y. EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene. 29: 5850-60. PMID 20676128 DOI: 10.1038/Onc.2010.313 |
0.814 |
|
| 2010 |
Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proceedings of the National Academy of Sciences of the United States of America. 107: 13252-7. PMID 20616078 DOI: 10.1073/Pnas.0913476107 |
0.572 |
|
| 2010 |
Lindzen M, Lavi S, Leitner O, Yarden Y. Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proceedings of the National Academy of Sciences of the United States of America. 107: 12559-63. PMID 20616021 DOI: 10.1073/Pnas.1006218107 |
0.459 |
|
| 2010 |
Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, ... ... Yarden Y, et al. EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Science Signaling. 3: ra43. PMID 20516477 DOI: 10.1126/Scisignal.2000876 |
0.783 |
|
| 2010 |
Witsch E, Sela M, Yarden Y. Roles for Growth Factors in Cancer Progression Physiology. 25: 85-101. PMID 20430953 DOI: 10.1152/Physiol.00045.2009 |
0.42 |
|
| 2010 |
Pines G, Köstler WJ, Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. Febs Letters. 584: 2699-706. PMID 20388509 DOI: 10.1016/J.Febslet.2010.04.019 |
0.549 |
|
| 2010 |
Mills GB, Yarden Y. The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. Cancer Cell. 17: 217-8. PMID 20227035 DOI: 10.1016/J.Ccr.2010.02.023 |
0.371 |
|
| 2010 |
Köstler WJ, Yarden Y. The epidermal growth factor receptor family Handbook of Cell Signaling, 2/E. 2: 435-441. DOI: 10.1016/B978-0-12-374145-5.00061-9 |
0.548 |
|
| 2009 |
Tarcic G, Boguslavsky SK, Wakim J, Kiuchi T, Liu A, Reinitz F, Nathanson D, Takahashi T, Mischel PS, Ng T, Yarden Y. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Current Biology : Cb. 19: 1788-98. PMID 19836242 DOI: 10.1016/J.Cub.2009.09.048 |
0.523 |
|
| 2009 |
Mills GB, Jurisica I, Yarden Y, Norman JC. Genomic amplicons target vesicle recycling in breast cancer. The Journal of Clinical Investigation. 119: 2123-7. PMID 19620778 DOI: 10.1172/Jci40256 |
0.383 |
|
| 2009 |
Mosesson Y, Chetrit D, Schley L, Berghoff J, Ziv T, Carvalho S, Milanezi F, Admon A, Schmitt F, Ehrlich M, Yarden Y. Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling. Developmental Cell. 16: 687-98. PMID 19460345 DOI: 10.1016/J.Devcel.2009.03.015 |
0.551 |
|
| 2009 |
Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis Proceedings of the National Academy of Sciences of the United States of America. 106: 3294-3299. PMID 19218427 DOI: 10.1073/Pnas.0812059106 |
0.405 |
|
| 2009 |
Zwang Y, Yarden Y. Systems biology of growth factor-induced receptor endocytosis. Traffic (Copenhagen, Denmark). 10: 349-63. PMID 19183301 DOI: 10.1111/J.1600-0854.2008.00870.X |
0.813 |
|
| 2009 |
Schechter B, Ben-Kasus T, Yarden Y, Sela M. On the notion of synergy of monoclonal antibodies as drugs Communicative and Integrative Biology. 2: 477-478. DOI: 10.4161/Cib.2.6.9326 |
0.506 |
|
| 2009 |
Chaluvally-Raghavan P, Zeisel A, Koestler W, Jacob-Hirsch J, Rechavi G, Domany E, Yarden Y. HER2-Associated Breast Cancer Signature Using a 3D Culture Model. Cancer Research. 69: 4146-4146. DOI: 10.1158/0008-5472.Sabcs-09-4146 |
0.372 |
|
| 2008 |
Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nature Reviews. Cancer. 8: 835-50. PMID 18948996 DOI: 10.1038/Nrc2521 |
0.487 |
|
| 2008 |
Seger R, Rodeck U, Yarden Y. Meeting report: Receptor tyrosine kinases: The emerging tip of systems control Iet Systems Biology. 2: 1-4. DOI: 10.1049/Iet-Syb:20070048 |
0.504 |
|
| 2008 |
Yarden Y. The EGF receptor signalling system European Journal of Cancer Supplements. 6: 1. DOI: 10.1016/S1359-6349(08)71177-7 |
0.496 |
|
| 2008 |
Yarden Y, Schlessinger J. The EGF receptor kinase: Evidence for allosteric activation and intramolecular self-phosphorylation Growth Factors in Biology and Medicine. 23-45. DOI: 10.1002/9780470720974.ch3 |
0.652 |
|
| 2007 |
Ben-Kasus T, Schechter B, Sela M, Yarden Y. Cancer therapeutic antibodies come of age: Targeting minimal residual disease Molecular Oncology. 1: 42-54. PMID 19383286 DOI: 10.1016/J.Molonc.2007.01.003 |
0.324 |
|
| 2007 |
Amit I, Wides R, Yarden Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Molecular Systems Biology. 3: 151. PMID 18059446 DOI: 10.1038/Msb4100195 |
0.447 |
|
| 2007 |
Yarden Y, Shilo BZ. SnapShot: EGFR signaling pathway. Cell. 131: 1018. PMID 18045542 DOI: 10.1016/J.Cell.2007.11.013 |
0.396 |
|
| 2007 |
Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, ... ... Yarden Y, et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nature Cell Biology. 9: 961-9. PMID 17643115 DOI: 10.1038/Ncb1622 |
0.756 |
|
| 2007 |
Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proceedings of the National Academy of Sciences of the United States of America. 104: 10607-12. PMID 17556544 DOI: 10.1073/Pnas.0701286104 |
0.504 |
|
| 2007 |
Sundvall M, Peri L, Määttä JA, Tvorogov D, Paatero I, Savisalo M, Silvennoinen O, Yarden Y, Elenius K. Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene. 26: 6905-14. PMID 17486069 DOI: 10.1038/Sj.Onc.1210501 |
0.486 |
|
| 2007 |
Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, Citri A, Katz M, Lavi S, Ben-Basat Y, Benjamin S, Corso S, Gan J, Yosef RB, Giordano S, ... Yarden Y, et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene. 26: 6968-78. PMID 17486068 DOI: 10.1038/Sj.Onc.1210503 |
0.842 |
|
| 2007 |
Ben-Yosef R, Starr A, Karaush V, Loew V, Lev-Ari S, Barnea I, Lidawi G, Shtabsky A, Greif Y, Yarden Y, Vexler A. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. The Prostate. 67: 871-80. PMID 17440944 DOI: 10.1002/Pros.20555 |
0.345 |
|
| 2007 |
Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, ... ... Yarden Y, et al. A module of negative feedback regulators defines growth factor signaling. Nature Genetics. 39: 503-12. PMID 17322878 DOI: 10.1038/Ng1987 |
0.735 |
|
| 2007 |
Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Current Opinion in Cell Biology. 19: 124-34. PMID 17314037 DOI: 10.1016/J.Ceb.2007.02.008 |
0.527 |
|
| 2007 |
Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochimica Et Biophysica Acta. 1773: 1161-76. PMID 17306385 DOI: 10.1016/J.Bbamcr.2007.01.002 |
0.564 |
|
| 2007 |
Spector N, Xia W, El-Hariry I, Yarden Y, Bacus S. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors Breast Cancer Research. 9. DOI: 10.1186/bcr1652 |
0.406 |
|
| 2007 |
Zwang Y, Yarden Y. Growth factor signalling: ample opportunities for pharmaceutical interventions in oncology European Journal of Cancer, Supplement. 5: 427-429. DOI: 10.1016/S1359-6349(07)70086-1 |
0.734 |
|
| 2006 |
Zwang Y, Yarden Y. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. The Embo Journal. 25: 4195-206. PMID 16932740 DOI: 10.1038/Sj.Emboj.7601297 |
0.807 |
|
| 2006 |
Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nature Reviews. Molecular Cell Biology. 7: 505-16. PMID 16829981 DOI: 10.1038/Nrm1962 |
0.701 |
|
| 2006 |
Katz M, Mosesson Y, Yarden Y. In vitro and in vivo assays of monoubiquitination of receptor tyrosine kinases. Methods in Molecular Biology (Clifton, N.J.). 327: 115-29. PMID 16780216 DOI: 10.1385/1-59745-012-X:115 |
0.586 |
|
| 2006 |
Germano S, Barberis D, Santoro MM, Penengo L, Citri A, Yarden Y, Gaudino G. Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling. The Journal of Biological Chemistry. 281: 21710-9. PMID 16740632 DOI: 10.1074/Jbc.M602014200 |
0.784 |
|
| 2006 |
Oved S, Mosesson Y, Zwang Y, Santonico E, Shtiegman K, Marmor MD, Kochupurakkal BS, Katz M, Lavi S, Cesareni G, Yarden Y. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. The Journal of Biological Chemistry. 281: 21640-51. PMID 16735510 DOI: 10.1074/Jbc.M513034200 |
0.837 |
|
| 2006 |
Mosesson Y, Yarden Y. Monoubiquitylation: a recurrent theme in membrane protein transport. The Israel Medical Association Journal : Imaj. 8: 233-7. PMID 16671356 |
0.351 |
|
| 2006 |
Li R, Soosairajah J, Harari D, Citri A, Price J, Ng HL, Morton CJ, Parker MW, Yarden Y, Bernard O. Hsp90 increases LIM kinase activity by promoting its homo-dimerization. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 1218-20. PMID 16641196 DOI: 10.1096/Fj.05-5258Fje |
0.73 |
|
| 2006 |
Citri A, Harari D, Shohat G, Ramakrishnan P, Gan J, Lavi S, Eisenstein M, Kimchi A, Wallach D, Pietrokovski S, Yarden Y. Hsp90 recognizes a common surface on client kinases. The Journal of Biological Chemistry. 281: 14361-9. PMID 16551624 DOI: 10.1074/Jbc.M512613200 |
0.728 |
|
| 2006 |
Starr A, Greif J, Vexler A, Ashkenazy-Voghera M, Gladesh V, Rubin C, Kerber G, Marmor S, Lev-Ari S, Inbar M, Yarden Y, Ben-Yosef R. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. International Journal of Cancer. Journal International Du Cancer. 119: 269-74. PMID 16463386 DOI: 10.1002/Ijc.21818 |
0.437 |
|
| 2006 |
Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunology Letters. 104: 146-55. PMID 16384610 DOI: 10.1016/J.Imlet.2005.11.018 |
0.729 |
|
| 2005 |
Bacus S, Spector NL, Yarden Y. The era of ErbB-receptor-targeted therapies: advances toward personalized medicine. Personalized Medicine. 2: 301-315. PMID 29788579 DOI: 10.2217/17410541.2.4.301 |
0.378 |
|
| 2005 |
Sakaki Y, Kholodenko BN, Hatakeyama M, Kitano H, Kolch W, De Meyts P, Yarden Y, Westerhoff HV, Wiley HS. The International Consortium on Systems Biology of Receptor Tyrosine Kinase Regulatory Networks. Systems Biology. 152: 53-4. PMID 17044231 DOI: 10.1049/ip-syb:20059002 |
0.337 |
|
| 2005 |
Bacus SS, Gudkov AV, Esteva FJ, Yarden Y. Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. Breast Disease. 11: 63-75. PMID 15687593 DOI: 10.3233/Bd-1999-11106 |
0.434 |
|
| 2005 |
Rubin C, Gur G, Yarden Y. Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Research. 15: 66-71. PMID 15686631 DOI: 10.1038/Sj.Cr.7290268 |
0.56 |
|
| 2005 |
Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy Proceedings of the National Academy of Sciences of the United States of America. 102: 1915-1920. PMID 15684082 DOI: 10.1073/Pnas.0409610102 |
0.592 |
|
| 2005 |
Rubin C, Zwang Y, Vaisman N, Ron D, Yarden Y. Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. The Journal of Biological Chemistry. 280: 9735-44. PMID 15637081 DOI: 10.1074/Jbc.M408308200 |
0.812 |
|
| 2005 |
Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, Kerber G, Citri A, Lavi S, Eilam R, Chalifa-Caspi V, Eshhar Z, Pikarsky E, Pinkas-Kramarski R, Bacus SS, ... Yarden Y, et al. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. The Journal of Biological Chemistry. 280: 8503-12. PMID 15611079 DOI: 10.1074/Jbc.M413919200 |
0.795 |
|
| 2005 |
Kario E, Marmor MD, Adamsky K, Citri A, Amit I, Amariglio N, Rechavi G, Yarden Y. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. The Journal of Biological Chemistry. 280: 7038-48. PMID 15590694 DOI: 10.1074/Jbc.M408575200 |
0.792 |
|
| 2004 |
Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. Embo Reports. 5: 1165-70. PMID 15568014 DOI: 10.1038/Sj.Embor.7400300 |
0.787 |
|
| 2004 |
Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Seminars in Oncology. 31: 6-13. PMID 15490369 DOI: 10.1053/J.Seminoncol.2004.07.016 |
0.37 |
|
| 2004 |
Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. The Embo Journal. 23: 3270-81. PMID 15282549 DOI: 10.1038/Sj.Emboj.7600342 |
0.795 |
|
| 2004 |
Amit I, Yakir L, Katz M, Zwang Y, Marmor MD, Citri A, Shtiegman K, Alroy I, Tuvia S, Reiss Y, Roubini E, Cohen M, Wides R, Bacharach E, Schubert U, ... Yarden Y, et al. Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes & Development. 18: 1737-52. PMID 15256501 DOI: 10.1101/Gad.294904 |
0.831 |
|
| 2004 |
Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Seminars in Cancer Biology. 14: 262-70. PMID 15219619 DOI: 10.1016/J.Semcancer.2004.04.005 |
0.58 |
|
| 2004 |
Marmor MD, Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 23: 2057-70. PMID 15021893 DOI: 10.1038/Sj.Onc.1207390 |
0.598 |
|
| 2004 |
Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. International Journal of Radiation Oncology, Biology, Physics. 58: 903-13. PMID 14967450 DOI: 10.1016/J.Ijrobp.2003.06.002 |
0.601 |
|
| 2004 |
Gur G, Yarden Y. Enlightened receptor dynamics. Nature Biotechnology. 22: 169-70. PMID 14755288 DOI: 10.1038/Nbt0204-169 |
0.378 |
|
| 2004 |
Kochupurakkal BS, Yarden Y. Signaling by growth factor receptors. Methods in Molecular Biology (Clifton, N.J.). 250: 177-202. PMID 14755089 DOI: 10.1385/1-59259-671-1:177 |
0.513 |
|
| 2004 |
Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle (Georgetown, Tex.). 3: 51-60. PMID 14657666 DOI: 10.4161/Cc.3.1.607 |
0.776 |
|
| 2003 |
Shelly M, Mosesson Y, Citri A, Lavi S, Zwang Y, Melamed-Book N, Aroeti B, Yarden Y. Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. Developmental Cell. 5: 475-86. PMID 12967566 DOI: 10.1016/J.Devcel.2003.08.001 |
0.837 |
|
| 2003 |
Penengo L, Rubin C, Yarden Y, Gaudino G. c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene. 22: 3669-79. PMID 12802274 DOI: 10.1038/Sj.Onc.1206585 |
0.494 |
|
| 2003 |
Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J, Yarden Y. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. The Journal of Biological Chemistry. 278: 21323-6. PMID 12719435 DOI: 10.1074/Jbc.C300096200 |
0.836 |
|
| 2003 |
Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Experimental Cell Research. 284: 54-65. PMID 12648465 DOI: 10.1016/S0014-4827(02)00101-5 |
0.804 |
|
| 2003 |
Bao J, Gur G, Yarden Y. Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proceedings of the National Academy of Sciences of the United States of America. 100: 2438-43. PMID 12604776 DOI: 10.1073/Pnas.0437945100 |
0.544 |
|
| 2003 |
Rubin C, Litvak V, Medvedovsky H, Zwang Y, Lev S, Yarden Y. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Current Biology : Cb. 13: 297-307. PMID 12593795 DOI: 10.1016/S0960-9822(03)00053-8 |
0.849 |
|
| 2003 |
Shtiegman K, Yarden Y. The role of ubiquitylation in signaling by growth factors: implications to cancer. Seminars in Cancer Biology. 13: 29-40. PMID 12507554 DOI: 10.1016/S1044-579X(02)00097-4 |
0.572 |
|
| 2002 |
Huotari MA, Miettinen PJ, Palgi J, Koivisto T, Ustinov J, Harari D, Yarden Y, Otonkoski T. ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. Endocrinology. 143: 4437-46. PMID 12399441 DOI: 10.1210/En.2002-220382 |
0.464 |
|
| 2002 |
Katz M, Shtiegman K, Tal-Or P, Yakir L, Mosesson Y, Harari D, Machluf Y, Asao H, Jovin T, Sugamura K, Yarden Y. Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4. Traffic (Copenhagen, Denmark). 3: 740-51. PMID 12230472 DOI: 10.1034/J.1600-0854.2002.31006.X |
0.8 |
|
| 2002 |
Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, Yarden Y. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. The Embo Journal. 21: 2407-17. PMID 12006493 DOI: 10.1093/Emboj/21.10.2407 |
0.774 |
|
| 2002 |
Oved S, Yarden Y. Signal transduction: molecular ticket to enter cells. Nature. 416: 133-6. PMID 11894079 DOI: 10.1038/416133A |
0.344 |
|
| 2002 |
Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, Yarden Y. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. The Embo Journal. 21: 303-13. PMID 11823423 DOI: 10.1093/Emboj/21.3.303 |
0.571 |
|
| 2002 |
Yarden Y. Overview of HER2 and Type I growth factor receptor influences in breast cancer development and biology European Journal of Cancer. 38: S48. DOI: 10.1016/S0959-8049(02)80123-X |
0.435 |
|
| 2001 |
Yarden Y. Biology of HER2 and its importance in breast cancer Oncology. 61: 1-13. PMID 11694782 DOI: 10.1159/000055396 |
0.567 |
|
| 2001 |
Yarden Y. The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities European Journal of Cancer. 37. PMID 11597398 DOI: 10.1016/S0959-8049(01)00230-1 |
0.592 |
|
| 2001 |
Rubin I, Yarden Y. The basic biology of HER2. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 12: S3-8. PMID 11521719 DOI: 10.1093/Annonc/12.Suppl_1.S3 |
0.569 |
|
| 2001 |
Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman AM, Lipkowitz S. Cbl-b-dependent Coordinated Degradation of the Epidermal Growth Factor Receptor Signaling Complex Journal of Biological Chemistry. 276: 27677-27684. PMID 11375397 DOI: 10.1074/Jbc.M102641200 |
0.505 |
|
| 2001 |
Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 20: 147-55. PMID 11313944 DOI: 10.1038/Sj.Onc.1204062 |
0.353 |
|
| 2001 |
Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases Febs Letters. 490: 142-152. PMID 11223029 DOI: 10.1016/S0014-5793(01)02117-2 |
0.569 |
|
| 2001 |
Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. The Journal of Biological Chemistry. 276: 3702-8. PMID 11071886 DOI: 10.1074/Jbc.M006864200 |
0.423 |
|
| 2001 |
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. 2: 127-137. DOI: 10.1038/35052073 |
0.447 |
|
| 2000 |
Vaisman N, Nissim A, Klapper LN, Tirosh B, Yarden Y, Sela M. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunology Letters. 75: 61-7. PMID 11163868 DOI: 10.1016/S0165-2478(00)00278-9 |
0.408 |
|
| 2000 |
Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer Oncogene. 19: 6102-6114. PMID 11156523 DOI: 10.1038/Sj.Onc.1203973 |
0.558 |
|
| 2000 |
Hurwitz E, Klapper LN, Wilchek M, Yarden Y, Sela M. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Cancer Immunology, Immunotherapy : Cii. 49: 226-34. PMID 10941905 DOI: 10.1007/S002620000112 |
0.336 |
|
| 2000 |
Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M, Yarden Y. c-Cbl is a suppressor of the neu oncogene. The Journal of Biological Chemistry. 275: 35532-9. PMID 10940298 DOI: 10.1074/Jbc.M002661200 |
0.749 |
|
| 2000 |
Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Research. 60: 3384-8. PMID 10910043 |
0.352 |
|
| 2000 |
Zhu Z, Kleeff J, Friess H, Wang L, Zimmermann A, Yarden Y, Büchler MW, Korc M. Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochemical and Biophysical Research Communications. 273: 1019-24. PMID 10891365 DOI: 10.1006/Bbrc.2000.3033 |
0.38 |
|
| 2000 |
Bao J, Alroy I, Waterman H, Schejter ED, Brodie C, Gruenberg J, Yarden Y. Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome Journal of Biological Chemistry. 275: 26178-26186. PMID 10816576 DOI: 10.1074/Jbc.M002367200 |
0.589 |
|
| 2000 |
Kirschbaum MH, Yarden Y. The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms Journal of Cellular Biochemistry. 77: 52-60. PMID 10762015 DOI: 10.1002/(Sici)1097-4644(2000)77:34+<52::Aid-Jcb10>3.0.Co;2-X |
0.566 |
|
| 2000 |
Chausovsky A, Waterman H, Elbaum M, Yarden Y, Geiger B, Bershadsky AD. Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization. Oncogene. 19: 878-88. PMID 10702796 DOI: 10.1038/Sj.Onc.1203410 |
0.545 |
|
| 2000 |
Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Molecular and Cellular Biology. 20: 672-83. PMID 10611246 DOI: 10.1128/Mcb.20.2.672-683.2000 |
0.435 |
|
| 2000 |
Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors Advances in Cancer Research. 77: 25-79. PMID 10549355 |
0.515 |
|
| 2000 |
Alroy I, Yarden Y. Biochemistry of HER2 oncogenesis in breast cancer Breast Disease. 11: 31-48. DOI: 10.3233/Bd-1999-11104 |
0.591 |
|
| 2000 |
Bacus SS, Gudkov AV, Esteva FJ, Yarden Y. Expression of erbB receptors and their ligands in breast cancer: Implications to biological behavior and therapeutic response Breast Disease. 11: 63-75. |
0.322 |
|
| 1999 |
Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1 Molecular Cell. 4: 1029-1040. PMID 10635327 DOI: 10.1016/S1097-2765(00)80231-2 |
0.797 |
|
| 1999 |
Waterman H, Levkowitz G, Alroy I, Yarden Y. The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. The Journal of Biological Chemistry. 274: 22151-4. PMID 10428778 DOI: 10.1074/Jbc.274.32.22151 |
0.791 |
|
| 1999 |
Waterman H, Alroy I, Strano S, Seger R, Yarden Y. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing Embo Journal. 18: 3348-3358. PMID 10369675 DOI: 10.1093/Emboj/18.12.3348 |
0.592 |
|
| 1999 |
Brizzi MF, Dentelli P, Rosso A, Yarden Y, Pegoraro L. STAT protein recruitment and activation in c-Kit deletion mutants Journal of Biological Chemistry. 274: 16965-16972. PMID 10358045 DOI: 10.1074/Jbc.274.24.16965 |
0.489 |
|
| 1999 |
Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, Yarden Y. Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase Oncogene. 18: 2681-2689. PMID 10348342 DOI: 10.1038/Sj.Onc.1202631 |
0.591 |
|
| 1999 |
Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y. The erbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors Proceedings of the National Academy of Sciences of the United States of America. 96: 4995-5000. PMID 10220407 DOI: 10.1073/Pnas.96.9.4995 |
0.56 |
|
| 1999 |
Alroy I, Soussan L, Seger R, Yarden Y. Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor Molecular and Cellular Biology. 19: 1961-1972. PMID 10022883 DOI: 10.1128/Mcb.19.3.1961 |
0.528 |
|
| 1999 |
Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, ... ... Yarden Y, et al. ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network Molecular and Cellular Biology. 19: 8695-8695. DOI: 10.1128/mcb.19.12.8695 |
0.366 |
|
| 1999 |
Yarden Y. HER2/neu oncoprotein of human adenocarcinomas: an amplifier of signal transduction by stromal growth factor European Journal of Cancer. 35: S133. DOI: 10.1016/S0959-8049(99)80915-0 |
0.428 |
|
| 1998 |
Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes & Development. 12: 3663-74. PMID 9851973 DOI: 10.1101/Gad.12.23.3663 |
0.807 |
|
| 1998 |
Chausovsky A, Tsarfaty I, Kam Z, Yarden Y, Geiger B, Bershadsky AD. Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells. Molecular Biology of the Cell. 9: 3195-209. PMID 9802906 DOI: 10.1091/Mbc.9.11.3195 |
0.48 |
|
| 1998 |
Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC, Yarden Y. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. The Embo Journal. 17: 5948-63. PMID 9774339 DOI: 10.1093/Emboj/17.20.5948 |
0.785 |
|
| 1998 |
Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alamandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, ... ... Yarden Y, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network Molecular and Cellular Biology. 18: 6090-6101. PMID 9742126 DOI: 10.1128/Mcb.18.10.6090 |
0.553 |
|
| 1998 |
Lenferink AEG, Pinkas-Kramarski R, Van De Poll MLM, Van Vugt MJH, Klapper LN, Tzahar E, Waterman H, Sela M, Van Zoelen EJJ, Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers Embo Journal. 17: 3385-3397. PMID 9628875 DOI: 10.1093/Emboj/17.12.3385 |
0.602 |
|
| 1998 |
Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency Journal of Biological Chemistry. 273: 13819-13827. PMID 9593726 DOI: 10.1074/Jbc.273.22.13819 |
0.546 |
|
| 1998 |
Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang LM, Lyass L, Alimandi M, Kuo A, Bacus SS, Pierce JH, Andrews GC, Yarden Y. Epiregulin is a potent Pan-ErbB ligand that preferentially activates heterodimeric receptor complexes Journal of Biological Chemistry. 273: 10496-10505. PMID 9553109 DOI: 10.1074/Jbc.273.17.10496 |
0.578 |
|
| 1998 |
Pinkas-Kramarski R, Lenferink AEG, Bacus SS, Lyass L, Van De Poll MLM, Klapper LN, Tzahar E, Sela M, Van Zoelen EJJ, Yarden Y. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin Oncogene. 16: 1249-1258. PMID 9546426 DOI: 10.1038/Sj.Onc.1201642 |
0.598 |
|
| 1998 |
Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands Biochimica Et Biophysica Acta - Reviews On Cancer. 1377. PMID 9540810 DOI: 10.1016/S0304-419X(97)00032-2 |
0.594 |
|
| 1998 |
Eilam R, Pinkas-Kramarski R, Ratzkin BJ, Segal M, Yarden Y. Activity-dependent regulation of Neu differentiation factor/neuregulin expression in rat brain Proceedings of the National Academy of Sciences of the United States of America. 95: 1888-1893. PMID 9465112 DOI: 10.1073/Pnas.95.4.1888 |
0.442 |
|
| 1998 |
Zrihan-Licht S, Deng B, Yarden Y, McShan G, Keydar I, Avraham H. Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation Journal of Biological Chemistry. 273: 4065-4072. PMID 9461599 DOI: 10.1074/Jbc.273.7.4065 |
0.511 |
|
| 1998 |
Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, ... ... Yarden Y, et al. ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network Molecular and Cellular Biology. 18: 7602-7602. DOI: 10.1128/MCB.18.12.7602 |
0.366 |
|
| 1998 |
Bacus S, Yarden Y, Kaminsky D. Neu differentiation factor (NDF/heregulin) induces expression of adhesion molecules, increased cellular invasiveness, and is expressed in Paget's disease of the breast together with its receptors European Journal of Cancer. 34: S116. DOI: 10.1016/S0959-8049(98)80486-3 |
0.375 |
|
| 1997 |
Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: Cell lineage determination and oncogenesis through combinatorial signaling Journal of Mammary Gland Biology and Neoplasia. 2: 97-107. PMID 10882296 DOI: 10.1023/A:1026343528967 |
0.568 |
|
| 1997 |
Pinkas-Kramarski R, Eilam R, Alroy I, Levkowitz G, Lonai P, Yarden Y. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. Oncogene. 15: 2803-15. PMID 9419971 DOI: 10.1038/Sj.Onc.1201466 |
0.739 |
|
| 1997 |
Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y. Bivalence of EGF-like ligands drives the ErbB signaling network. The Embo Journal. 16: 4938-50. PMID 9305636 DOI: 10.1093/Emboj/16.16.4938 |
0.774 |
|
| 1997 |
Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions Febs Letters. 410: 83-86. PMID 9247128 DOI: 10.1016/S0014-5793(97)00412-2 |
0.557 |
|
| 1997 |
Burden S, Yarden Y. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis Neuron. 18: 847-855. PMID 9208852 DOI: 10.1016/S0896-6273(00)80324-4 |
0.403 |
|
| 1997 |
Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors Oncogene. 14: 2099-2109. PMID 9160890 DOI: 10.1038/Sj.Onc.1201029 |
0.551 |
|
| 1997 |
Yarden Y. Growth factors and ErbB/HER tyrosine kinases: How do they contribute to malignancy? European Journal of Cancer. 33: S223-S224. DOI: 10.1016/S0959-8049(97)85780-2 |
0.465 |
|
| 1996 |
Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies British Journal of Cancer. 74: 1749-1756. PMID 8956788 DOI: 10.1038/Bjc.1996.625 |
0.338 |
|
| 1996 |
Kristt DA, Yarden Y. Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes: Implications for glial oncogenesis Cancer. 78: 1272-1283. PMID 8826951 DOI: 10.1002/(Sici)1097-0142(19960915)78:6<1272::Aid-Cncr16>3.0.Co;2-Y |
0.526 |
|
| 1996 |
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Molecular and Cellular Biology. 16: 5276-87. PMID 8816440 DOI: 10.1128/Mcb.16.10.5276 |
0.801 |
|
| 1996 |
Mincione G, Bianco C, Kannan S, Colletta G, Ciardiello F, Sliwkowski M, Yarden Y, Normanno N, Pramaggiore A, Kim N, Salomon DS. Enhanced Expression Of Heregulin In C-Erb B-2 And C-Ha-Ras Transformed Mouse And Human Mammary Epithelial Cells Journal of Cellular Biochemistry. 60: 437-446. PMID 8707884 DOI: 10.1002/(Sici)1097-4644(19960315)60:4<437::Aid-Jcb1>3.0.Co;2-T |
0.337 |
|
| 1996 |
Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations Journal of Biological Chemistry. 271: 19029-19032. PMID 8702572 DOI: 10.1074/Jbc.271.32.19029 |
0.542 |
|
| 1996 |
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. The Embo Journal. 15: 2452-67. PMID 8665853 DOI: 10.1002/J.1460-2075.1996.Tb00603.X |
0.812 |
|
| 1996 |
Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene. 12: 1117-25. PMID 8649804 |
0.769 |
|
| 1996 |
Brizzi MF, Aronica MG, Rosso A, Bagnara GP, Yarden Y, Pegoraro L. Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes Journal of Biological Chemistry. 271: 3562-3567. PMID 8631962 DOI: 10.1074/Jbc.271.7.3562 |
0.457 |
|
| 1996 |
Chen X, Levkowitz G, Tzahar E, Karunagaran D, Lavi S, Ben-Baruch N, Leitner O, Ratzkin BJ, Bacus SS, Yarden Y. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. The Journal of Biological Chemistry. 271: 7620-9. PMID 8631797 DOI: 10.1074/Jbc.271.13.7620 |
0.81 |
|
| 1996 |
Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors American Journal of Pathology. 148: 549-558. PMID 8579117 |
0.489 |
|
| 1996 |
Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Molecular and Cellular Biology. 15: 6496-505. PMID 8524214 DOI: 10.1128/Mcb.15.12.6496 |
0.514 |
|
| 1996 |
Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. The Embo Journal. 15: 254-264. DOI: 10.1002/J.1460-2075.1996.Tb00356.X |
0.598 |
|
| 1995 |
Lu HS, Chang D, Philo JS, Zhang K, Narhi LO, Liu N, Zhang M, Sun J, Wen J, Yanagihara D, Karunagaran D, Yarden Y, Ratzkin B. Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. Journal of Biological Chemistry. 270: 4784-4791. PMID 7876251 DOI: 10.1074/Jbc.270.9.4784 |
0.336 |
|
| 1995 |
Marte BM, Jeschke M, Graus-Porta D, Taverna D, Hofer P, Groner B, Yarden Y, Hynes NE. Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. Molecular Endocrinology (Baltimore, Md.). 9: 14-23. PMID 7760847 DOI: 10.1210/Mend.9.1.7760847 |
0.452 |
|
| 1995 |
Karunagaran D, Tzahar E, Liu N, Wen D, Yarden Y. Neu differentiation factor inhibits EGF binding: A model for trans-regulation within the ErbB family of receptor tyrosine kinases Journal of Biological Chemistry. 270: 9982-9990. PMID 7730382 DOI: 10.1074/Jbc.270.17.9982 |
0.59 |
|
| 1995 |
Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake Proceedings of the National Academy of Sciences of the United States of America. 92: 3353-3357. PMID 7724565 DOI: 10.1073/Pnas.92.8.3353 |
0.375 |
|
| 1995 |
Gilboa L, Ben-Levy R, Yarden Y, Henis YI. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits Journal of Biological Chemistry. 270: 7061-7067. PMID 7706244 DOI: 10.1074/Jbc.270.13.7061 |
0.556 |
|
| 1995 |
Dong Z, Brennan A, Liu N, Yarden Y, Lefkowitz G, Mirsky R, Jessen KR. Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron. 15: 585-96. PMID 7546738 DOI: 10.1016/0896-6273(95)90147-7 |
0.421 |
|
| 1995 |
Migdal M, Soker S, Yarden Y, Neufeld G. Activation of a transfected FGFR-1 receptor in Madin-Darby epithelial cells results in a reversible loss of epithelial properties Journal of Cellular Physiology. 162: 266-276. PMID 7529769 DOI: 10.1002/Jcp.1041620212 |
0.452 |
|
| 1995 |
Blechman JM, Lev S, Barg J, Eisenstein M, Vaks B, Vogel Z, Givol D, Yarden Y.. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell. 80: 103-113. PMID 7529140 DOI: 10.1016/0092-8674(95)90455-7 |
0.846 |
|
| 1995 |
Blechman JM, Yarden Y. Structural aspects of receptor dimerization. c-Kit as an example Annals of the New York Academy of Sciences. 766: 344-362. PMID 7486681 DOI: 10.1111/J.1749-6632.1995.Tb26685.X |
0.402 |
|
| 1994 |
Stancovski I, Sela M, Yarden Y. Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase Cancer Treatment and Research. 71: 161-191. PMID 7946947 DOI: 10.1007/978-1-4615-2592-9_9 |
0.544 |
|
| 1994 |
Bacus SS, Zelnick CR, Plowman G, Yarden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers: Implication for tumor biology and clinical behavior American Journal of Clinical Pathology. 102. PMID 7942609 |
0.464 |
|
| 1994 |
Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway Embo Journal. 13: 3302-3311. PMID 7913890 DOI: 10.1002/J.1460-2075.1994.Tb06632.X |
0.457 |
|
| 1994 |
Ben-Baruch N, Yarden Y. Neu Differentiation Factors: A Family of Alternatively Spliced Neuronal and Mesenchymal Factors Proceedings of the Society For Experimental Biology and Medicine. 206: 221-227. PMID 7912439 DOI: 10.3181/00379727-206-43746 |
0.534 |
|
| 1994 |
Lev S, Blechman JM, Givol D, Yarden Y. Steel factor and c-kit protooncogene: Genetic lessons in signal transduction Critical Reviews in Oncogenesis. 5: 141-168. PMID 7531500 DOI: 10.1615/Critrevoncog.V5.I2-3.30 |
0.83 |
|
| 1994 |
Lev S, Blechman JM, Givol D, Yarden Y.. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit Rev Oncog.. 5: 141-68. PMID 7531500 DOI: 10.1615/critrevoncog.v5.i2-3.30 |
0.86 |
|
| 1994 |
Brizzi MF, Zini MG, Aronica MG, Blechman JM, Yarden Y, Pegoraro L. Convergence of signaling by interleukin-3, granulocyte-macrophage colony- stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase Journal of Biological Chemistry. 269: 31680-31684. PMID 7527392 |
0.463 |
|
| 1994 |
Brizzi MF, Blechman JM, Cavalloni G, Givol D, Yarden Y, Pegoraro L. Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells Oncogene. 9: 1583-1589. PMID 7514283 |
0.395 |
|
| 1993 |
Normanno N, Qi CF, Gullick WJ, Persico G, Yarden Y, Wen D, Plowman G, Kenney N, Johnson G, Kim N, Brandt R, Martinez-Lacaci I, Dickson RB, Salomon DS. Expression of amphiregulin, cripto-1, and heregulin-alpha in human breast-cancer cells. International Journal of Oncology. 2: 903-911. PMID 21573645 DOI: 10.3892/Ijo.2.6.903 |
0.342 |
|
| 1993 |
Kelman Z, Simon-Chazottes D, Guénet JL, Yarden Y. The murine vik gene (chromosome 9) encodes a putative receptor with unique protein kinase motifs Oncogene. 8: 37-44. PMID 8380921 |
0.368 |
|
| 1993 |
Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. The Embo Journal. 12: 961-71. PMID 8096177 DOI: 10.1002/J.1460-2075.1993.Tb05737.X |
0.79 |
|
| 1993 |
Orr-Urtreger A, Trakhtenbrot L, Ben-Levy R, Wen D, Rechavi G, Lonai P, Yarden Y. Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. Proceedings of the National Academy of Sciences of the United States of America. 90: 1867-71. PMID 8095334 DOI: 10.1073/Pnas.90.5.1867 |
0.369 |
|
| 1993 |
Peles E, Yarden Y. Neu and its ligands: from an oncogene to neural factors. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 15: 815-24. PMID 7908191 DOI: 10.1002/Bies.950151207 |
0.811 |
|
| 1993 |
Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. Journal of Immunology (Baltimore, Md. : 1950). 151: 6577-82. PMID 7902379 |
0.399 |
|
| 1993 |
Blechman JM, Lev S, Givol D, Yarden Y. Structure-function analyses of the Kit receptor for the steel factor Stem Cells. 11: 12-21. PMID 7691317 DOI: 10.1002/Stem.5530110804 |
0.806 |
|
| 1993 |
Blechman JM, Lev S, Givol D, Yarden Y.. Structure-function analyses of the kit receptor for the steel factor. Stem Cells.. 12-21. PMID 7691317 DOI: 10.1002/stem.5530110804 |
0.842 |
|
| 1993 |
Kristt DA, Reedy E, Yarden Y. Receptor tyrosine kinase expression in astrocytic lesions: Similar features in gliosis and glioma Neurosurgery. 33: 106-115. PMID 7689190 DOI: 10.1227/00006123-199307000-00017 |
0.461 |
|
| 1993 |
Zakut R, Perlis R, Eliyahu S, Yarden Y, Givol D, Lyman SD, Halaban R. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells Oncogene. 8: 2221-2229. PMID 7687762 |
0.344 |
|
| 1993 |
Lev S, Blechman J, Nishikawa SI, Givol D, Yarden Y. Interspecies molecular chimeras of kit help define the binding site of the stem cell factor Molecular and Cellular Biology. 13: 2224-2234. PMID 7681144 DOI: 10.1128/Mcb.13.4.2224 |
0.458 |
|
| 1993 |
Lev S, Blechman J, Nishikawa S, Givol D, Yarden Y.. Interspecies molecular chimeras of kit help define the binding site of the stem cell factor. Mol Cell Biol.. 13: 2224-34.. PMID 7681144 DOI: 10.1128/mcb.13.4.2224 |
0.821 |
|
| 1993 |
Blechman JM, Lev S, Brizzi MF, Leitner O, Pegoraro L, Givol D, Yarden Y. Soluble c-Kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor Journal of Biological Chemistry. 268: 4399-4406. PMID 7680037 |
0.365 |
|
| 1993 |
Kristt DA, Reedy E, Yarden Y. Receptor Tyrosine Kinase Expression in Astrocytic Lesions Neurosurgery. 33: 106-115. DOI: 10.1097/00006123-199307000-00017 |
0.435 |
|
| 1992 |
Lev S, Yarden Y, Givol D. Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor Journal of Biological Chemistry. 267: 15970-15977. PMID 1379243 |
0.813 |
|
| 1992 |
Lev S, Yarden Y, Givol D. A recombinant ectodomain of the receptor for the Stem Cell Factor (SCF) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responses Journal of Biological Chemistry. 267: 10866-10873. PMID 1375232 |
0.812 |
|
| 1992 |
Bacus SS, Stancovski l, Hurwitz E, Mills GB, Ullrich A, Chin D, Huberman E, Sela M, Yarden Y. Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells Cancer Research. 52: 2580-2589. PMID 1373672 |
0.331 |
|
| 1992 |
Funasaka Y, Boulton T, Cobb M, Yarden Y, Fan B, Lyman SD, Williams DE, Anderson DM, Zakut R, Mishima Y. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Molecular Biology of the Cell. 3: 197-209. PMID 1372524 DOI: 10.1091/Mbc.3.2.197 |
0.517 |
|
| 1992 |
Lev S, Givol D, Yarden Y. Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase Proceedings of the National Academy of Sciences of the United States of America. 89: 678-682. PMID 1370584 DOI: 10.1073/Pnas.89.2.678 |
0.811 |
|
| 1992 |
Lev S, Givol D, Yarden Y.. Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. Proc Natl Acad Sci U S a.. 89: 678-82. PMID 1370584 DOI: 10.1073/pnas.89.2.678 |
0.846 |
|
| 1992 |
Stancovski I, Peles E, Ben Levy R, Lemprecht R, Kelman Z, Goldman-Michael R, Hurwitz E, Bacus S, Sela M, Yarden Y. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy. The Journal of Steroid Biochemistry and Molecular Biology. 43: 95-103. PMID 1356018 DOI: 10.1016/0960-0760(92)90192-L |
0.802 |
|
| 1992 |
Ben-Levy R, Peles E, Goldman-Michael R, Yarden Y. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity. The Journal of Biological Chemistry. 267: 17304-13. PMID 1355090 |
0.76 |
|
| 1992 |
Peles E, Lamprecht R, Ben-Levy R, Tzahar E, Yarden Y. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation. The Journal of Biological Chemistry. 267: 12266-74. PMID 1351056 |
0.757 |
|
| 1992 |
Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Levy RB, Koski RA, Lu HS, Yarden Y. Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit Cell. 69: 559-572. PMID 1349853 DOI: 10.1016/0092-8674(92)90456-M |
0.749 |
|
| 1992 |
Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden Y. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell. 69: 205-16. PMID 1348215 DOI: 10.1016/0092-8674(92)90131-U |
0.757 |
|
| 1992 |
Yayon A, Zimmer Y, Shen GH, Avivi A, Yarden Y, Givol D. A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. The Embo Journal. 11: 1885-90. PMID 1316275 DOI: 10.1002/J.1460-2075.1992.Tb05240.X |
0.546 |
|
| 1992 |
Hemmerich S, Yarden Y, Pecht I. A cromoglycate binding protein from rat mast cells of a leukemia line is a nucleoside diphosphate kinase Biochemistry. 31: 4574-4579. PMID 1316151 DOI: 10.1021/Bi00134A006 |
0.417 |
|
| 1992 |
Yarden Y. Cell activation: Genetic approaches. Advances in regulation of cell growth. Vol. 2 Molecular Immunology. 29: 697-698. DOI: 10.1016/0161-5890(92)90207-E |
0.34 |
|
| 1992 |
Avivi A, Zimmer Y, Yayon A, Yarden Y, Givol D. Corrigendum: Flg-2, a new member of the family of fibroblast growth factor receptors (Oncogene (1991) 6 (1089-1092)) Oncogene. 7: 823. |
0.328 |
|
| 1991 |
Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth Proceedings of the National Academy of Sciences of the United States of America. 88: 8691-8695. PMID 1717984 DOI: 10.1073/Pnas.88.19.8691 |
0.475 |
|
| 1991 |
Raz V, Kelman Z, Avivi A, Neufeld G, Givol D, Yarden Y. PCR-based identification of new receptors: Molecular cloning of a receptor for fibroblast growth factors Oncogene. 6: 753-760. PMID 1711190 |
0.496 |
|
| 1991 |
Lev S, Givol D, Yarden Y. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor Embo Journal. 10: 647-654. PMID 1705885 DOI: 10.1002/J.1460-2075.1991.Tb07993.X |
0.86 |
|
| 1991 |
Kashles O, Yarden Y, Fischer R, Ullrich A, Schlessinger J. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Molecular and Cellular Biology. 11: 1454-63. PMID 1705006 DOI: 10.1128/Mcb.11.3.1454 |
0.726 |
|
| 1991 |
Peles E, Levy RB, Or E, Ullrich A, Yarden Y. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. The Embo Journal. 10: 2077-86. PMID 1676673 DOI: 10.1002/J.1460-2075.1991.Tb07739.X |
0.797 |
|
| 1991 |
Yarden Y, Peles E. Biochemical analysis of the ligand for the neu oncogenic receptor. Biochemistry. 30: 3543-50. PMID 1672825 DOI: 10.1021/Bi00228A027 |
0.788 |
|
| 1991 |
Orr-Urtreger A, Givol D, Yayon A, Yarden Y, Lonai P. Developmental expression of two murine fibroblast growth factor receptors, flg and bek Development. 113: 1419-1434. PMID 1667382 |
0.353 |
|
| 1991 |
Avivi A, Zimmer Y, Yayon A, Yarden Y, Givol D. Flg-2, a new member of the family of fibroblast growth factor receptors Oncogene. 6: 1089-1092. PMID 1648703 |
0.368 |
|
| 1991 |
Yarden Y, Kelman Z. Transmembrane signalling receptors for cytokines and growth factors Current Opinion in Structural Biology. 1: 582-589. DOI: 10.1016/S0959-440X(05)80081-8 |
0.546 |
|
| 1990 |
Yarden Y. Receptor-like oncogenes: Functional analysis through novel experimental approaches Molecular Immunology. 27: 1319-1324. PMID 1980338 DOI: 10.1016/0161-5890(90)90037-Z |
0.515 |
|
| 1990 |
Goldman R, Levy RB, Peles E, Yarden Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry. 29: 11024-8. PMID 1980216 DOI: 10.1021/Bi00502A002 |
0.799 |
|
| 1990 |
Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active Proceedings of the National Academy of Sciences of the United States of America. 87: 2569-2573. PMID 1969636 DOI: 10.1073/Pnas.87.7.2569 |
0.521 |
|
| 1990 |
Lev S, Yarden Y, Givol D. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene Molecular and Cellular Biology. 10: 6064-6068. PMID 1700279 DOI: 10.1128/Mcb.10.11.6064 |
0.833 |
|
| 1990 |
Lev S, Yarden Y, Givol D.. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene. Mol Cell Biol.. 10: 6064-8.. PMID 1700279 DOI: 10.1128/mcb.10.11.6064 |
0.864 |
|
| 1989 |
Yarden Y, Weinberg RA. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proceedings of the National Academy of Sciences of the United States of America. 86: 3179-83. PMID 2470093 DOI: 10.1073/Pnas.86.9.3179 |
0.67 |
|
| 1988 |
Yarden Y, Ullrich A. Molecular analysis of signal transduction by growth factors Biochemistry. 27: 3113-3119. PMID 3291942 DOI: 10.1021/Bi00409A001 |
0.389 |
|
| 1988 |
Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases Annual Review of Biochemistry. 57: 443-478. PMID 3052279 DOI: 10.1146/Annurev.Bi.57.070188.002303 |
0.606 |
|
| 1988 |
Seger R, Yarden Y, Kashles O, Goldblatt D, Schlessinger J, Shaltiel S. The epidermal growth factor receptor as a substrate for a kinase-splitting membranal proteinase. The Journal of Biological Chemistry. 263: 3496-500. PMID 2830286 |
0.707 |
|
| 1987 |
Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry. 26: 1443-51. PMID 3494473 DOI: 10.1021/Bi00379A035 |
0.744 |
|
| 1987 |
Yarden Y, Schlessinger J. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry. 26: 1434-42. PMID 3494472 DOI: 10.1021/Bi00379A034 |
0.753 |
|
| 1987 |
Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. The Embo Journal. 6: 3341-51. PMID 2448137 DOI: 10.1002/J.1460-2075.1987.Tb02655.X |
0.722 |
|
| 1986 |
Ullrich A, Riedel H, Yarden Y, Coussens L, Gray A, Dull T, Schlessinger J, Waterfield MD, Parker PJ. Protein kinases in cellular signal transduction: tyrosine kinase growth factor receptors and protein kinase C. Cold Spring Harbor Symposia On Quantitative Biology. 51: 713-24. PMID 3472757 DOI: 10.1101/Sqb.1986.051.01.084 |
0.711 |
|
| 1986 |
Yarden Y, Escobedo JA, Kuang WJ, Yang-Feng TL, Daniel TO, Tremble PM, Chen EY, Ando ME, Harkins RN, Francke U. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature. 323: 226-32. PMID 3020426 DOI: 10.1038/323226A0 |
0.537 |
|
| 1986 |
Yarden Y, Rodriguez H, Wong SKF, Brandt DR, May DC, Burnier J, Harkins RN, Chen EY, Ramachandran J, Ullrich A. The avian β-adrenergic receptor: Primary structure and membrane topology Proceedings of the National Academy of Sciences of the United States of America. 83: 6795-6799. PMID 3018746 DOI: 10.1073/Pnas.83.18.6795 |
0.405 |
|
| 1986 |
Zidovetzki R, Yarden Y, Schlessinger J, Jovin TM. Microaggregation of hormone-occupied epidermal growth factor receptors on plasma membrane preparations. The Embo Journal. 5: 247-50. PMID 3011399 DOI: 10.1002/J.1460-2075.1986.Tb04205.X |
0.678 |
|
| 1985 |
Yarden Y, Schlessinger J. The EGF receptor kinase: evidence for allosteric activation and intramolecular self-phosphorylation. Ciba Foundation Symposium. 116: 23-45. PMID 3000707 |
0.717 |
|
| 1985 |
Yarden Y, Harari I, Schlessinger J. Purification of an active EGF receptor kinase with monoclonal antireceptor antibodies. The Journal of Biological Chemistry. 260: 315-9. PMID 2578126 |
0.703 |
|
| 1984 |
Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309: 418-25. PMID 6328312 DOI: 10.1038/309418A0 |
0.682 |
|
| 1984 |
Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307: 521-7. PMID 6320011 DOI: 10.1038/307521A0 |
0.748 |
|
| 1984 |
Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Research. 44: 753-60. PMID 6318976 |
0.584 |
|
| 1984 |
Lax I, Bar-Eli M, Yarden Y, Libermann TA, Schlessinger J. Antibodies to two defined regions of the transforming protein pp60src interact specifically with the epidermal growth factor receptor kinase system. Proceedings of the National Academy of Sciences of the United States of America. 81: 5911-5. PMID 6207534 DOI: 10.1073/Pnas.81.19.5911 |
0.741 |
|
| 1983 |
Schlessinger J, Schreiber AB, Levi A, Lax I, Libermann T, Yarden Y. Regulation of cell proliferation by epidermal growth factor. Crc Critical Reviews in Biochemistry. 14: 93-111. PMID 6301752 DOI: 10.3109/10409238309102791 |
0.73 |
|
| 1983 |
Schreiber AB, Libermann TA, Lax I, Yarden Y, Schlessinger J. Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. The Journal of Biological Chemistry. 258: 846-53. PMID 6296087 |
0.674 |
|
| 1983 |
Gooi HC, Schlessinger J, Lax I, Yarden Y, Libermann TA, Feizi T. Monoclonal antibody reactive with the human epidermal-growth-factor receptor recognizes the blood-group-A antigen. Bioscience Reports. 3: 1045-52. PMID 6198005 DOI: 10.1007/Bf01121031 |
0.623 |
|
| 1983 |
Hapgood J, Libermann TA, Lax I, Yarden Y, Schreiber AB, Naor Z, Schlessinger J. Monoclonal antibodies against epidermal growth factor receptor induce prolactin synthesis in cultured rat pituitary cells (GH3). Proceedings of the National Academy of Sciences of the United States of America. 80: 6451-5. PMID 6195656 DOI: 10.1073/Pnas.80.21.6451 |
0.732 |
|
| 1983 |
Yarden Y, Schlessinger J. Phosphoamino acid specificity of the EGF-receptor kinase system in normal mitogenically responsive human cells Cell Biology International Reports. 7: 533-534. DOI: 10.1016/0309-1651(83)90164-9 |
0.697 |
|
| 1982 |
Moolenaar WH, Yarden Y, de Laat SW, Schlessinger J. Epidermal growth factor induces electrically silent Na+ influx in human fibroblasts. The Journal of Biological Chemistry. 257: 8502-6. PMID 6979542 |
0.548 |
|
| 1982 |
Schlessinger J, Schreiber AB, Lax I, Yashuv-Gan Y, Libermann TA, Hillman GM, Levi A, Yarden Y. Molecular steps in the action and regulation of epidermal growth factor: a cellular mitogen. Progress in Clinical and Biological Research. 91: 359-72. PMID 6292947 |
0.613 |
|
| 1982 |
Yarden Y, Schreiber AB, Schlessinger J. A nonmitogenic analogue of epidermal growth factor induces early responses mediated by epidermal growth factor. The Journal of Cell Biology. 92: 687-93. PMID 6282891 DOI: 10.1083/Jcb.92.3.687 |
0.661 |
|
| 1981 |
Schreiber AB, Lax I, Yarden Y, Eshhar Z, Schlessinger J. Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proceedings of the National Academy of Sciences of the United States of America. 78: 7535-9. PMID 6278478 DOI: 10.1073/Pnas.78.12.7535 |
0.693 |
|
| 1981 |
Zidovetzki R, Yarden Y, Schlessinger J, Jovin TM. Rotational diffusion of epidermal growth factor complexed to cell surface receptors reflects rapid microaggregation and endocytosis of occupied receptors. Proceedings of the National Academy of Sciences of the United States of America. 78: 6981-5. PMID 6273899 DOI: 10.1073/Pnas.78.11.6981 |
0.675 |
|
| 1981 |
Schreiber AB, Yarden Y, Schlessinger J. A non-mitogenic analogue of epidermal growth factor enhances the phosphorylation of endogenous membrane proteins. Biochemical and Biophysical Research Communications. 101: 517-23. PMID 6272761 DOI: 10.1016/0006-291X(81)91290-0 |
0.706 |
|
| 1981 |
Yarden Y, Gabbay M, Schlessinger J. Primary amines do not prevent the endocytosis of epidermal growth factor into 3T3 fibroblasts. Biochimica Et Biophysica Acta. 674: 188-203. PMID 6263349 DOI: 10.1016/0304-4165(81)90377-9 |
0.673 |
|
| Show low-probability matches. |